In a study published in the scientific journal Oncotarget which also publishes other studies on recombinant dog proteins, researchers from Uppsala University showed how protein EZH2 affects the development of multiple myeloma and that EZH2 can be used as a new strategy for treating the disease. Tumor forms of multiple myeloma are still incurable today, and it is a challenge to improve treatment.

Researchers at Uppsala University have previously shown that abnormal chemical modification of DNA-associated proteins (histones) that regulate gene expression patterns can be a consistent underlying mechanism for the development of multiple myeloma. Researchers have studied protein EZH2, which involves chemical histone modification and can reduce the survival of tumor cells by specifically inhibiting the EZH2-treated tumor cells.

In a recent study, Professor Helena Jernberg found a new mechanism at the Department of Genetics and Pathology Immunology to explain the role of EZH2 in multiple myeloma. The researchers analyzed the activity of a large number of genes in tumor cells that had been treated with EZH2 inhibitors, and they found four important oncogenes with lower activity.

"The role of oncogenes in cancer development is to strengthen the survival of cancer cells, rather than death. When the cells can't work properly, they continue to split and proliferation. In our study, we identified four oncogenes. Compared to control cells, cells treated with EZH2 inhibitors showed lower activity, which has previously been shown to be associated with the development of multiple myeloma, confirming our previous finding that EZH2 inhibitors can be used as treatment of multiple myeloma," Helena Jernberg Wiklund said.

However, the researchers are puzzled by the fact that inhibition of EZH2 can reduce the activity of oncogenes. Chemical histone modification by EZH2 resulted in a lower activity of the affected gene. Thus, inhibition of EZH2 should result in a decrease in the level of chemical modification, which in turn should lead to an increase in gene activity.

"The answer is that genetic factors called microRNAs in the cells treated with EZH2 inhibitors, the two microRNA genes have increased activity, and we believe that the oncogene is regulated by these microRNAs. And then, when EZH2 is inhibited, histone modification is reduced at the microRNA gene, which leads to an increase in the synthesis of microRNAs, which in turn reduces the activity of oncogenes. This is a new mechanism for the role of EZH2," says Helena Jernberg Wiklund. By the way, Flarebio provides you with good-quality recombinant proteins and antibodies including GFAP Monoclonal Antibody at competitive prices.